News & Analysis on Clinical Trial Services & Contract Research And Development
News from USP, Icon, and Novella – People on the move
By Natalie Morrison
- Last updated on
The US Pharmacopeial Convention (USP) has added new chief officers for science, information technology, global alliances and international standards to its executive team.
Promotions were handed to former vice president of information technology Scott Henderson, who is now the organisation’s chief information officer, as well as Angela Long who moves from her role as vice president of healthcare quality standards and compendial affairs to become chief of global alliances and organisational affairs.
Long-serving employee V. Srini Srinivasan has played key roles in establishing USP’s laboratory and office facilities in India, China, and Brazil. He now oversees operations in the countries as chief international sites and standards officer.
And finally Praveen Tyle is new to USP, and will be the chief science officer. Prior to joining USP Tyle spent 27 years in senior executive global leadership positions in R&D, manufacturing, quality, business development and operations.
Icon has named Colin Stanley as president of DOCS, its global resourcing division.
Stanley – who joined the business in 2001 – was previously the Chief Operating Officer of DOCS.
Ciaran Murray, CEO of Icon said: “Through the various roles that Colin has held within Icon, he has gained a thorough understanding of both the Icon organisation and the global clinical research and resourcing markets.
“This experience will be invaluable as we continue to develop the resourcing arm of our business.”
Novella has named Catherine Tyner as its new executive director of oversight group management.
Tyner joins Novella from Quintiles, where she served as a senior director in the Lifecycle Safety unit.
In her new role, she will focus on advancing the firm’s technical solutions which they offer for oversight group operations.
She said: "Significant benefits can be gained by utilising technology to facilitate the data reviews conducted by all five types of clinical oversight groups.
“Delivering the full scope of oversight group activities through an industry-leading, integrated electronic platform is a natural progression for Novella's eClinical model."
Raymond Kaiser will become Covance’s new global science leader and VP for biotechnology services.
He joins the team from Merck Research Laboratories, where he was executive director of bioprocess R&D.
He replaces Carl Martin, who is set to retire after a 35-year career at the firm.
Kaiser said:“I am eager to have the opportunity to work with some of the top minds in the field and apply my decades of biotech development experience to help Covance clients bring new products to market.”
Sucampo has drafted Cary Claiborne as its new chief financial officer (CFO).
Claiborne was first appointed to the company in March as interim CFO, joining the company from New Generations Biofuels, where he was president and CEO.
Ryuji Ueno, chairman and CEO of Sucampo said: “I believe he will help bring Sucampo to the next level.”